NZ’s PHARMAC has agreed to
fund Revolade (eltrombopag), a
new drug for a rare and potentially
fatal blood disorder, idiopathic
thrombocytopenic purpura (ITP).
PHARMAC estimates that about
40 patients will receive the product
at a cost of $36,000 per patient per
year starting 01 Jan 2014.
And in other PHARMAC news, a
new agreement with GSK sees the
Special Authority criteria removed
from Seretide, and anti-viral
influenza treatment zanamavir
(Relenza) plus Revolade will be
listed while the price will reduce
on all three currently listed asthma
inhalers as a trade-off.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Dec 13
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.